An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren’t conclusive

Pfizer and Valneva have reported that their experimental Lyme disease vaccine demonstrated effectiveness in preventing the tick-borne illness during a recent clinical trial, although the findings are not yet conclusive. The companies are now seeking regulatory review for this potential breakthrough, marking the first new vaccine against Lyme disease in decades.

The development of this vaccine is significant as it represents a potential advancement in public health efforts to combat Lyme disease, which has seen rising incidence rates. If approved, it could provide a new preventive measure for at-risk populations.